Orient International Enterprise, Ltd. (SHA:600278)

Marinus Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,142	4,578	4,921	5,041	4,799	5,776
Trading Asset Securities	117.49	49.55	155.37	239.94	268.34	118.35
Cash & Short-Term Investments	4,259	4,627	5,076	5,280	5,068	5,894
Cash Growth	-14.47%	-8.85%	-3.86%	4.20%	-14.02%	44.71%
Accounts Receivable	4,514	4,514	3,211	2,425	2,517	2,313
Other Receivables	806.47	991	710.4	954.24	752.03	494.85
Receivables	5,321	5,545	3,921	3,412	3,352	2,842
Inventory	2,275	1,681	1,464	2,373	2,134	1,613
Prepaid Expenses	-	14.99	12.2	-	-	2.73
Other Current Assets	3,186	2,652	2,816	3,933	3,495	3,693
Total Current Assets	15,041	14,521	13,290	14,999	14,049	14,045
Property, Plant & Equipment	1,236	1,251	1,323	1,455	1,500	1,130
Long-Term Investments	2,298	2,419	1,962	1,892	2,166	2,056
Goodwill	0	0	0	0	-	-
Other Intangible Assets	263.35	263.5	269.33	276.79	285.56	310.63
Long-Term Accounts Receivable	11.55	14.92	10.36	9.87	14.43	15.41
Long-Term Deferred Tax Assets	159.63	159.53	137.65	181.85	177.88	147.02
Long-Term Deferred Charges	53.64	51.64	35.43	41.35	49.85	30.47
Other Long-Term Assets	133.07	136.8	115.31	137.44	192.82	186.08
Total Assets	19,196	18,817	17,143	18,994	18,434	17,920
Accounts Payable	5,500	5,699	4,198	4,156	4,178	3,779
Accrued Expenses	75.58	259.27	259.31	265.4	262.04	185.58
Short-Term Debt	744.39	582.94	353.65	669.15	1,010	824.18
Current Portion of Long-Term Debt	39.69	0.75	-	68.02	141.47	42.27
Current Portion of Leases	-	41.71	36.74	45.32	48.45	-
Current Income Taxes Payable	37	52.25	72.22	65.32	63.49	147.97
Current Unearned Revenue	3,584	2,932	3,359	4,909	4,117	4,257
Other Current Liabilities	825.81	800.63	741.61	911.96	736.47	647.5
Total Current Liabilities	10,806	10,369	9,021	11,091	10,557	9,884
Long-Term Debt	12.3	18.05	13.93	0.75	124.27	271.05
Long-Term Leases	202.59	209.63	198.73	197.83	217.69	-
Long-Term Unearned Revenue	5.68	5.29	5.76	6.4	7.09	8.29
Long-Term Deferred Tax Liabilities	260.68	286.57	198.7	242.3	274.86	339.86
Other Long-Term Liabilities	7.1	7.1	0.63	0.26	2.42	1.96
Total Liabilities	11,309	10,911	9,453	11,551	11,191	10,514
Common Stock	877.77	877.77	882.93	882.26	868.46	868.46
Additional Paid-In Capital	2,765	2,765	2,787	2,778	2,721	2,943
Retained Earnings	3,165	3,109	3,057	2,893	2,625	2,329
Treasury Stock	-27.58	-27.58	-62.93	-59.52	-	-
Comprehensive Income & Other	742.29	826.01	626	568.8	699.96	978.21
Total Common Equity	7,522	7,550	7,290	7,063	6,915	7,118
Minority Interest	365.69	356.43	400.67	380.45	328.31	287.93
Shareholders' Equity	7,888	7,906	7,690	7,443	7,243	7,406
Total Liabilities & Equity	19,196	18,817	17,143	18,994	18,434	17,920
Total Debt	998.98	853.07	603.05	981.07	1,542	1,138
Net Cash (Debt)	3,260	3,774	4,473	4,299	3,525	4,757
Net Cash Growth	-23.57%	-15.63%	4.05%	21.95%	-25.88%	38.88%
Net Cash Per Share	3.70	4.36	5.10	4.89	4.07	6.33
Filing Date Shares Outstanding	877.14	877.77	882.93	883.97	883.53	868.46
Total Common Shares Outstanding	877.77	877.77	882.93	882.26	868.46	868.46
Working Capital	4,235	4,152	4,270	3,908	3,491	4,161
Book Value Per Share	8.57	8.60	8.26	8.01	7.96	8.20
Tangible Book Value	7,259	7,286	7,020	6,786	6,629	6,807
Tangible Book Value Per Share	8.27	8.30	7.95	7.69	7.63	7.84
Land	-	-	-	-	52.2	52.2
Buildings	-	1,136	1,292	1,273	1,200	1,069
Machinery	-	988.55	999.46	1,168	1,094	1,040
Construction In Progress	-	53.97	35.35	5.24	9.42	61.79

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.